1-methyl-3-carbamoyl>-1,4-dihydropyridine | 84455-00-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-methyl-3-carbamoyl>-1,4-dihydropyridine
• 英文别名: 1-Methyl-3-{N-[β-(4-hydroxy-3-methoxyphenyl)ethyl]}carbamoyl-1,4-dihydropyridine；1-Methyl-3-{N-[beta-(4-hydroxy-3-methoxyphenyl)ethyl]}carbamoyl-1,4-dihydropyridine；N-[2-(4-hydroxy-3-methoxyphenyl)ethyl]-1-methyl-4H-pyridine-3-carboxamide
• CAS: 84455-00-5
• 化学式: C₁₆H₂₀N₂O₃
• 分子量: 288.346
• InChiKey: RJSOJVXFFHRDSL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  61.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-methyl-3-carbamoyl>pyridinium iodide 在 sodium dithionite 、 碳酸氢钠 作用下， 以 水 、 乙酸乙酯 为溶剂， 反应 0.33h， 生成 1-methyl-3-carbamoyl>-1,4-dihydropyridine
  参考文献：
  名称：

  通过生物膜改善递送。13.多巴胺与二氢吡啶的脑特异性递送，与吡啶鎓盐型氧化还原递送系统平衡。

  摘要：

  与吡啶鎓盐型氧化还原递送系统平衡的二氢吡啶用于脑特异性递送多巴胺。体内施用邻苯二酚保护的多巴胺与1,4-二氢甘油三苯胺作为载体，导致大脑特异性，高浓度和持续浓度的1-甲基-3- [N-β-（3,4-二羟基苯基）多巴胺的直接前体乙基] [氨基甲酰基]吡啶鎓盐在大脑中锁定了多个小时，而全身浓度迅速下降，不到30分钟以1/2的速度下降。在大脑中观察到了明显的多巴胺能活性，持续了几个小时。

  DOI：

  10.1021/jm00358a013

文献信息

• Brain-specific drug delivery of steroid sex hormones cleaved from
  申请人：University of Florida

  公开号：US04900837A1

  公开（公告）日：1990-02-13

  The subject compounds, which are adapted for the site-specific/sustained delivery of centrally acting drug species to the brain, are: (a) compounds of the formula [D--DHC] (I) wherein [D] is a centrally acting drug species, and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine.revreaction.pyridinium salt redox carrier, with the proviso that when [DHC] is ##STR1## wherein R is lower alkyl or benzyl and [D] is a drug species containing a single NH.sub.2 or OH functional group, the single OH group when present being a primary or secondary OH group, said drug species being linked directly through said NH.sub.2 or OH function group to the carbonyl function of [DHC], then [D] must be other than a sympathetic stimulant, steroid sex hormone or long chain alkanol; and (b) non-toxic pharmaceutically acceptable salts of compounds of formula (I) wherein [D] is a centrally acting drug species and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine.revreaction.pyridinium salt redox carrier. The corresponding ionic pyridinium salt type drug/carrier entitles [D--QC].sup.+ X.sup.- are also disclosed.

  这些化合物适用于特定部位/持续性地将中枢神经系统药物物种传递到大脑，其中包括：（a）公式[D--DHC]（I）的化合物，其中[D]是中枢神经系统药物物种，[DHC]是二氢吡啶盐氧化还原载体的还原、可生物氧化、穿过血脑屏障的脂质形式，但当[DHC]为##STR1##其中R为低级烷基或苄基，[D]为含有单个NH.sub.2或OH官能团的药物物种，当存在单个OH官能团时，其为一级或二级OH官能团，该药物物种通过NH.sub.2或OH功能团直接连接到[DHC]的羰基功能团，则[D]必须不是交感神经兴奋剂、类固醇性激素或长链烷醇；以及（b）公式（I）的化合物的非毒性药用可接受盐，其中[D]是中枢神经系统药物物种，[DHC]是二氢吡啶盐氧化还原载体的还原、可生物氧化、穿过血脑屏障的脂质形式。还公开了相应的离子吡啶盐型药物/载体[D--QC].sup.+ X.sup.-。
• Brain-specific drug delivery
  申请人：University of Florida

  公开号：US05187158A1

  公开（公告）日：1993-02-16

  The subject compounds, which are adapted for the site-specific/sustained delivery of centrally acting drug species to the brain, are: (a) compounds of the formula [D-DHC] (I) wherein [D] is a centrally acting drug species, and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine .revreaction. pyridinium salt redox carrier, with the proviso that when [DHC] is ##STR1## wherein R is lower alkyl or benzyl and [D] is a drug species containing a single NH.sub.2 or OH functional group, the single OH group when present being a primary or secondary OH group, said drug species being linked directly through said NH.sub.2 or OH functional group to the carbonyl function of [DHC], then [D] must be other than a sympathetic stimulant, steroid sex hormone or long chain alkanol; and (b) non-toxic pharmaceutically acceptable salts of compounds of formula (I) wherein [D] is a centrally acting drug species and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine .revreaction. pyridinium salt redox carrier. The corresponding ionic pyridinium salt type drug/carrier entities [D-QC].sup.+ X.sup.- are also disclosed.

  这些化合物适用于针对特定部位/持续释放中枢作用药物物种到达大脑，其中包括：（a）式[D-DHC]（I）的化合物，其中[D]是中枢作用药物物种，[DHC]是一种二氢吡啶的还原、可生物氧化、穿越血脑屏障的脂质形式.revreaction.吡啶盐氧化还原载体，但当[DHC]为##STR1##其中R为较低的烷基或苄基，[D]是含有单个NH.sub.2或OH官能团的药物物种，当存在单个OH官能团时，该官能团为一次级或二次级OH官能团，该药物物种直接通过所述NH.sub.2或OH官能团与[DHC]的羰基功能相连结，那么[D]必须是除了交感神经兴奋剂、类固醇性激素或长链烷醇之外的其他药物物种；以及（b）公认为无毒的药物可接受盐，其中[D]是中枢作用药物物种，[DHC]是一种二氢吡啶的还原、可生物氧化、穿越血脑屏障的脂质形式.revreaction.吡啶盐氧化还原载体的化合物的式（I）。还公开了相应的离子吡啶盐型药物/载体实体[D-QC].sup.+ X.sup.-。
• Brain-specific dopaminergic activity involving dihydropyridine
  申请人：University of Florida

  公开号：US04727079A1

  公开（公告）日：1988-02-23

  A brain-specific dopaminergic response is elicited in a patient in need of such treatment, e.g., a patient afflicted with Parkinson's disease of hyperprolactinemia, by administering thereto a therapeutically effective amount of preferably catechol protected dopamine tethered to a reduced, blood-brain barrier penetrating lipoidal form [D-DHC] of a dihydropyridine.revreaction.pyridinium salt type redox carrier, e.g., 1,4-dihydrotrigonelline. Oxidation of the dihydropyridine carrier moiety in vivo to the ionic pyridinium salt type dopamine/carrier entity [D-QC].sup.+ prevents elimination thereof from the brain, while elimination from the general circulation is accelerated, resulting in significant and prolongedly sustained brain-specific dopaminergic activity.

  在需要这种治疗的患者（例如，帕金森病或高催乳素血症患者）中，通过向其施用治疗有效量的优选儿茶酚保护的多巴胺，该多巴胺与一种还原的、穿过血脑屏障的脂质形式[D-DHC]的吡啶鎓盐型氧化还原载体，例如1,4-二氢三甲基咖啡碱。体内二氢吡啶载体基团的氧化形成离子型吡啶鎓盐型多巴胺/载体实体[D-QC] +，防止其从大脑中消除，同时加速从全身循环中的消除，导致显著且持续时间长的大脑特异性多巴胺能活性。
• Brain-specific delivery of dopamine utilizing dihydropyridine/pyridinium
  申请人：University of Florida

  公开号：US04880816A1

  公开（公告）日：1989-11-14

  A brain-specific dopaminergic response is elicited in a patient in need of such treatment, e.g., a patient afflicted with Parkinson's disease of hyperprolactinemia, by administering thereto a therapeutically effective amount of preferably catechol protected dopamine tethered to a reduced, blood-brain barrier penetrating lipoidal form [D-DHC] of a dihydropyridine.revreaction.pyridinium salt type redox carrier, e.g., 1,4-dihydrotrigonelline. Oxidation of the dihydropyridine carrier moiety in vivo to the ionic pyridinium salt type dopamine/carrier entity [D-QC].sup.+ prevents elimination thereof from the brain, while elimination from the general circulation is accelerated, resulting in significant and prolongedly sustained brain-specific dopaminergic activity.

  在需要此类治疗的患者身上，例如患有帕金森病或高泌乳素血症的患者，通过向其施用治疗有效量的优选儿茶酚保护的多巴胺，该多巴胺与一种还原的、能穿过血脑屏障的脂质形式[D-DHC]的二氢吡啶盐型氧化还原载体，例如1,4-二氢三甲基咖啡碱结合。体内二氢吡啶载体基团的氧化形成离子型吡啶盐型多巴胺/载体实体[D-QC]sup.+，防止其从大脑中消失，同时加速其从全身循环中消除，从而导致显著且长期持续的大脑特异性多巴胺能活性。
• BODOR, NICHOLAS S.
  作者：BODOR, NICHOLAS S.

  DOI：——

  日期：——